Executive’s Perspective on Ohio’s Global Leadership in Health Care

I recently spoke with Dr. David Scholl, president and CEO of Diagnostic HYBRIDS, about his thoughts on Ohio’s health care leadership in the global marketplace and work-life balance.

Diagnostic HYBRIDS invents, develops, manufactures and sells innovative diagnostic and analytical products for a wide range of viral respiratory diseases, herpes virus infections, and other specific viral and thyroid diseases. The company also develops and commercializes innovative and genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry, with an initial focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines.

Diagnostic HYBRIDS recently announced the FDA clearance, for marketing under 510(k) pre-notification process, of Thyretain TSI Reporter BioAssay. Thyretain is the first FDA-cleared test that specifically detects thyroid stimulating immunoglobulins (TSI) and is to be used as an aid in the differential diagnosis of Graves’ disease, an autoimmune thyroid disorder.

Dr. Scholl believes Ohio’s promise is authentic: You can achieve professional success within the context of a fulfilling life. Short commutes allow him to have quality time with his family and enjoy the beauty of the outdoors. It’s the perfect work-life balance.

For Dr. Scholl, operating a business in Ohio means being competitive in the global marketplace. He takes pride in working at a world-class company right here in Ohio.

Check out the interview with Dr. Scholl to find out more about Ohio’s global leadership in the health care industry and his thoughts on work-life balance.

•  Print This Post
•  Forward this article to a friend
• Published under Bioscience & Bioproducts, Region 11 - Southeast Ohio